Eli Lilly
Eli Lilly and Company is a global pharmaceutical enterprise involved in the research, clinical development, manufacturing, and marketing of human healthcare products. The company's therapeutic core spans endocrinology, oncology, immunology, and neuroscience. Principal revenue drivers consist of key proprietary medicines, notably tirzepatide formulations sold under the brand names Mounjaro and Zepbound, alongside oncology and immunology treatments like Verzenio and Taltz. Its end markets encompass healthcare systems, retail pharmacy networks, government purchasers, and patients globally. Eli Lilly holds a market-leading international position in diabetes and metabolic health treatments. Headquartered in Indianapolis, Indiana, the company's common stock trades publicly on the New York Stock Exchange.
199 of the funds FundTelligence covers report a position in Eli Lilly.
- Legal name
- Eli Lilly & Co
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 199
- Exposure themes
- Incretin & GLP-1 Therapies, Multiple, Obesity, Obesity & Metabolic Health, Treatment, Women's Health
Funds holding Eli Lilly
- BlackRock iShares MSCI World Health Care Sector ESG UCITS ETF — BlackRock · 11.35 % (full portfolio disclosed, October 2026)
- AB International Health Care Portfolio — AllianceBernstein · 10.56 % (largest positions only, September 2026)
- Handelsbanken Helse Tema — Handelsbanken · 10.27 % (full portfolio disclosed, October 2026)
- Polar Capital Global Healthcare Select Fund — Polar Capital · 10.1 % (largest positions only, October 2026)
- Fidelity Global Healthcare Fund — Fidelity · 10.0 % (largest positions only, October 2026)
- Fondita Healthcare — Fondita · 9.88 % (largest positions only, October 2026)
- Swedbank Robur Healthcare — Swedbank · 9.86 % (full portfolio disclosed, October 2026)
- BNP Health Care Innovators — BNP Paribas · 9.8 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 199 funds holding it.